The combination of the upcoming European Biotechnology Act and the EMA’s new clinical trial targets is creating a uniquely competitive and innovation-friendly environment for clinical research in the EU.
At the core of the Biotech Act is a drive to simplify, streamline, and accelerate clinical trial assessments in Europe — making the region more attractive to sponsors, bringing more R&D investment to the EU, and working to make timelines competitive with the rest of the world.
The EMA’s new targets are ambitious:
- To add 500 additional multinational clinical trials over the next five years (an increase of about 100 per year over the current average of 900 authorized annually).
- To ensure that two-thirds (66%) of clinical trials begin recruiting patients within 200 days of application submission, compared to 50% today.
Notably, the EMA experts are also discussing in several forums a 60-day review window for clinical trial applications review which would further accelerate timelines and enhance Europe’s attractiveness for global research.
Key Opportunities for Sponsors:
- Streamlined regulatory framework — the European Biotech Act aims to harmonize and simplify regulations across member states, reducing approval timelines and legal uncertainties, especially for advanced and innovative therapies. This means faster access to market and smoother multinational trial execution for sponsors and CROs.
- Centralized and coordinated clinical trials — with EMA’s new targets and ACT EU initiatives, the EU is focusing on faster patient recruitment and increasing the number of multinational trials. This improves access to diverse patient populations and accelerates study timelines, making Europe a highly attractive region for global studies.
- Support for innovation and advanced therapies — both initiatives emphasize support for new biotechnologies, real-world evidence, and digital transformation — including AI and data-driven approaches — encouraging sponsors and CROs to innovate with confidence.
- Enhanced collaboration and investment — new framework encourages collaboration between sponsors, CROs, regulators, and ethics committees, fostering a more supportive research ecosystem and attracting investment into European clinical research.
How Palleos is preparing:
- Palleos is proactively adapting its operational models and SOPs to align with the new harmonized frameworks, ensuring rapid and compliant trial start-up across Europe.
- We are expanding our capabilities in advanced therapies and non-interventional studies, leveraging our regional knowledge and operational flexibility to help sponsors benefit from the EU’s innovation-driven environment.
- We are investing in digital tools and AI to enhance our operations —always with strong safeguards to ensure quality and compliance.
- Our teams are closely monitoring regulatory updates and participating in industry forums, ensuring we remain at the forefront of best practices and can guide our clients through the evolving landscape.
In summary, with these developments, Europe is rapidly becoming one of the most competitive, efficient, and innovative regions for international clinical research. The new regulatory environment presents a clear window of opportunity for sponsors willing to adapt their strategies.
We at Palleos, as an experienced Germany-based CRO, are excited to help our partners navigate this shift. With our proven therapeutic expertise across multiple therapeutic areas including oncology, rheumatology, infectious diseases, and cardiology, we leverage our deep regional knowledge to turn regulatory strategy into operational success. If you are interested in exploring how these changes can benefit your specific clinical development projects, please contact us to discuss your clinical research needs. We invite you to learn more about our comprehensive service portfolio and clinical research expertise on our website: palleos.com
